Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2020 > Hospital

Annual Report 2020

Department of Safety Management, Office of Infection Control and Prevention

Satoshi Iwata, Osamu Kobayashi, Mika, Shiotsuka, Yusuke Okuma, Junya Oguma, Kiyoko Nakano, Mimiko Muroya, Minako Hitokuwata, Tomomi Sano, Kouji Yamada, Anna Ishida

Introduction

 The mission of the Office of Infection Control and Prevention is to prevent and control healthcare-associated infections in cancer patients who undergo various cancer care including highly advanced cancer treatments. The office consists of infectious disease specialists, certified nurses in infection control, board certified pharmacists in infection control, an infection control microbiological technologist, and an office clerk. We execute our tasks in collaboration with the Infection Control Team and the Antimicrobial Stewardship Team which consists of cross-sectional members from various areas throughout our hospital. We also collaborate with “link nurses” to facilitate appropriate infection control practice in each ward.

The Team and What We Do

  • Advise on infection control and prevention, especially focusing on healthcare-associated infections, problematic pathogens including multidrug-resistant bacteria or SARS-CoV-2, and occupational infections.
  • Consult with physicians on appropriate diagnosis of and treatment for infectious diseases (Table).
  • Implement antimicrobial stewardship strategy based on the local data from our hospital and the current clinical evidence (Table).
  • Make weekly rounds in the wards to monitor the environmental maintenance and the compliance with the Infection Prevention and Control Manual.
  • Conduct surveillance for healthcare-associated infections and drug-resistant bacteria.
  • Provide education to the staff on standard practices regarding infection control and prevention with up-to-date evidence.
  • Check the immunization status of the hospital staff and vaccinate those with insufficient protective immunity.
  • Advise on building and refurbishment projects from the perspective of infection control.
  • Hold conferences or mutual site visits with other regional hospitals to promote improvement in one another’s infection control and prevention practices.

Table. Number of patients supported through ICT/AST rounds
Table. Number of patients supported through ICT/AST rounds

Table. Number of patients supported through ICT/AST rounds
Table. Number of patients supported through ICT/AST rounds

Research activities

  • Effective education on infection control practices, especially medical device management.
  • Surveillance for surgical site infections.
  • Appropriate dosing of antimicrobial drugs in cancer patients.
  • Ideal system of infection control for cancer centers in the Japanese medical care system.
  • Mechanism of antimicrobial resistance of multidrug-resistant strains of Enterobacteriaceae isolated from cancer patients.
  • Molecular epidemiology of Streptococci and Mycoplasma pneumoniae.
  • Epidemiology of bacterial meningitis in Japan.
  • COVID-19 and its vaccine in cancer patients.

Education

 Training for infection control and management of infectious diseases aimed at physicians and medical personnel.

Future Prospects

 Our final goal is to establish an ideal and feasible model of an infection control system for cancer centers around the world.

List of papers published in 2020

Journal

1. Ito A, Kobayashi K, Shiotsuka M, Sato T, Omura G, Matsumoto Y, Ikeda A, Sakai A, Eguchi K, Takano T, Matsumoto F, Kobayashi O, Iwata S, Yoshimoto S. Uniform infection screening allowed safe head and neck surgery during the coronavirus disease 2019 pandemic in Japan. Jpn J Clin Oncol, 51:400-407, 2021

2. Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, Matsushita H, Iwata S, Yamashita K, Atarashi Y, Watanabe S, Ide N, Yoshida T, Ohmagari N, Mitsuya H, Hamada A. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep, 11:5198, 2021

3. Oishi T, Muratani T, Tanaka T, Sato M, Kohdera U, Ouchi K, Iwata S, Matsumoto T, Nakahama C. Study of normal flora in the pharynx of healthy children. Jpn J Infect Dis, 2021

4. Shibata M, Morozumi M, Maeda N, Komiyama O, Shiro H, Iwata S, Ubukata K. Relationship between intrapartum antibiotic prophylaxis and group B streptococcal colonization dynamics in Japanese mother-neonate pairs. J Infect Chemother, 27:977-983, 2021

5. Baba K, Yoshida T, Shiotsuka M, Kobayashi O, Iwata S, Ohe Y. Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient. Lung Cancer, 153:182-183, 2021

6. Iwata S, Takata M, Morozumi M, Miyairi I, Matsubara K, Ubukata K. Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: Longitudinal analysis from 2002 to 2016 in Japan. J Infect Chemother, 27:604-612, 2021

7. Ishiwada N, Fujimaki K, Matsumoto T, Kiyota H, Tateda K, Sato J, Hanaki H, Takayanagi R, Yamaguchi Y, Hoshino T, Kuroki H, Iwata S, Tajima T, Horikoshi Y, Shiro H, Bamba M, Kawamura N, Ouchi K, Matsubara K, Okada T, Furuno K, Tsumura N. Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: General overview of pathogenic antimicrobial susceptibility. J Infect Chemother, 27:139-150, 2021

8. Ubukata K, Wajima T, Takata M, Murayama SY, Morozumi M, Mukae H, Ishida T, Miyairi I, Kiyota H, Iwata S. Molecular epidemiological characterization in mucoid-type Streptococcus pneumoniae isolates obtained from invasive pneumococcal disease patients in Japan. J Infect Chemother, 27:211-217, 2021

9. Saitoh A, Saitoh A, Katsuta T, Mine M, Kamiya H, Miyairi I, Ishiwada N, Oshiro M, Kira R, Shimizu N, Suga S, Tsugawa T, Fujioka M, Miyazaki C, Morioka I, Korematsu S, Nakano T, Tanaka-Taya K, Yoshikawa T, Iwata S, Kusuhara K, Azuma H, Moriuchi H, Okabe N, Hosoya M, Tsutsumi H, Okada K. Effect of a vaccine information statement (VIS) on immunization status and parental knowledge, attitudes, and beliefs regarding infant immunization in Japan. Vaccine, 38:8049-8054, 2020

10. Hosoba R, Makita S, Shiotsuka M, Kobayashi O, Nakano K, Muroya M, Okada N, Suzuki M, Ida H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Maeshima AM, Matsushita H, Yamamoto N, Ohe Y, Iwata S, Izutsu K. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop, 60:174-178, 2020

11. Morozumi M, Tajima T, Sakuma M, Shouji M, Meguro H, Saito K, Iwata S, Ubukata K. Sequence Type Changes Associated with Decreasing Macrolide-Resistant Mycoplasma pneumoniae, Japan. Emerg Infect Dis, 26:2210-2213, 2020

12. Kondo T, Okabayashi K, Sugiura K, Obara H, Takeuchi H, Wada N, Takano Y, Iwata S, Hasegawa N, Kitagawa Y. Effectiveness of active nasal surveillance culture for Methicillin-resistant Staphylococcus aureus in patients undergoing colorectal surgery. J Infect Chemother, 26:1244-1248, 2020

13. Shinjoh M, Yamaguchi Y, Furuichi M, Yaginuma M, Takahashi T, Iwata S. Recent trends in pediatric bacterial meningitis in Japan, 2016-2018 - S. agalactiae has been the most common pathogen. J Infect Chemother, 26:1033-1041, 2020

14. Tamaoka S, Shindo J, Tsuchihashi T, Bamba M, Iwata S. A 9-year-old boy with a sinus-related epidural abscess caused by Listeria monocytogenes. Pediatr Int, 62:502-503, 2020